To compare the efficacy and safety of basal insulin peglispro (BIL), which has a flat pharmacokinetic and pharmacodynamic profile and a long duration of action, with insulin glargine (GL) in patients with type 1 diabetes.In this phase III, 52-week, blinded study, we randomized 1114 adults with type 1 diabetes in a 3 : 2 distribution to receive either BIL (n = 664) or GL (n = 450) at bedtime, with preprandial insulin lispro, using intensive insulin management. The primary objective was to compare glycated haemoglobin (HbA1c) in the groups at 52 weeks, with a non-inferiority margin of 0.4

作者：R M, Bergenstal；H, Lunt；E, Franek；F, Travert；J, Mou；Y, Qu；C J, Antalis；M L, Hartman；M, Rosilio；S J, Jacober；E J, Bastyr

来源：Diabetes, obesity & metabolism 2016 年 18卷 11期